Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

David Malka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7664-0130; OpenAlex author ID A5017132355. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
86
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 6 papers · 2025: 1 paper · 2026: 1 paper

Papers 22

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  2. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  3. [Hereditary and familial forms of pancreatic adenocarcinoma: Genetic determinism, patients eligible for systematic screening, screening methods and results]. Co-author DOI 10.1016/j.bulcan.2023.11.002↗
  4. Codon-specific KRAS mutations predict survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2023.100030↗
  5. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2024.05.032↗
  6. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  7. Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study. Co-author DOI 10.1186/s12885-024-12016-z↗
  8. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… First author DOI 10.1200/jco.23.00795↗
  9. The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients. Co-author DOI 10.1007/s10620-022-07733-z↗
  10. Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations. Co-author DOI 10.3390/biomedicines11092569↗
  11. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  12. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Co-author DOI 10.1016/j.clinre.2020.101607↗
  13. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Co-author DOI 10.1200/jco.20.03329↗
  14. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/j.ejca.2020.05.018↗
  15. Systemic treatment of pancreatic cancer revisited. Co-author DOI 10.1053/j.seminoncol.2018.12.003↗
  16. An update on treatment options for pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835919875568↗
  17. Chemotherapy for pancreatic cancer: the rise of multidrug regimens. Co-author DOI 10.1016/s2468-1253(18)30235-8↗
  18. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
  19. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. Co-author DOI 10.1007/s11136-015-1198-x↗
  20. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Co-author DOI 10.1245/s10434-014-3898-9↗
  21. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  22. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastat… Co-author DOI 10.1016/j.ejca.2014.09.015↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Antoine Hollebecque · 6 shared papers, 2019–2024 · strength 0.87
  2. Michel Pierre Ducreux · 7 shared papers, 2014–2024 · strength 0.87
  3. Cristina Smolenschi · 5 shared papers, 2019–2024 · strength 0.74
  4. Anthony Tarabay · 4 shared papers, 2023–2024 · strength 0.65
  5. Alice Boilève · 4 shared papers, 2023–2024 · strength 0.65
  6. Jean‐Baptiste Bachet · 5 shared papers, 2015–2026 · strength 0.59
  7. Olivier Bouché · 3 shared papers, 2021–2026 · strength 0.50
  8. Isabelle Trouilloud · 4 shared papers, 2014–2026 · strength 0.42
  9. Thierry Conroy · 5 shared papers, 2014–2019 · strength 0.41
  10. Rémy Nicolle · 2 shared papers, 2024–2026 · strength 0.39
  11. Julien Taı̈eb · 5 shared papers, 2014–2026 · strength 0.39
  12. Laëtitia Dahan · 3 shared papers, 2014–2026 · strength 0.37
  13. Jean–Marc Phelip · 2 shared papers, 2021–2026 · strength 0.34
  14. Pierre Laurent‐Puig · 2 shared papers, 2019–2026 · strength 0.34
  15. Antoîne Italiano · 2 shared papers, 2024 · strength 0.30
  16. Fanny Jaulin · 2 shared papers, 2024 · strength 0.30
  17. Alain Sauvanet · 3 shared papers, 2014–2024 · strength 0.28
  18. Yves Rinaldi · 2 shared papers, 2021–2024 · strength 0.26
  19. Nicolas Williet · 2 shared papers, 2021–2024 · strength 0.26
  20. Raëf Abdallah · 1 shared paper, 2026 · strength 0.24
  21. Shulin Zhao · 1 shared paper, 2026 · strength 0.24
  22. Jerome F. Cros · 1 shared paper, 2026 · strength 0.24
  23. Louis de Mestier · 1 shared paper, 2026 · strength 0.24
  24. Baiyong Shen · 1 shared paper, 2026 · strength 0.24
  25. Vinciane Rebours · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.